ArticleFrontiers in psychiatry2026
Global and item-level MADRS differences between melancholic and unspecified depressive symptoms under rTMS: an exploratory analysis.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Repetitive transcranial magnetic stimulation (rTMS) has demonstrated efficacy in treating major depressive disorder (MDD), but evidence regarding its use across the different depressive subtypes remains limited. Objective: To observe changes in overall MADRS scores and individual MADRS items in patients diagnosed with melancholic depressive features versus those with non-melancholic and non-atypical depressive features following rTMS. Methods: An exploratory prospective study was conducted involving 21 participants presenting with depressive symptomatology either with melancholic (n=11) or unspecified features, meaning non-melancholic and non-atypical (n=10). All subjects underwent a standardized 15-session rTMS protocol. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) before and after treatment. Results: After adjusting for confounding factors, an association was observed between the unspecified group and the greater reduction in the overall MADRS score (B = -9.08, 95% CI -17.69 to -0.46, p = 0.040). Significant results were also found for individual items of inner tension (B = -2.05, 95% CI -3.57 to -0.52, p = 0.012) and inability to feel (B = -1.94, 95% CI -3.10 to -0.78, p = 0.003). Conclusions: Our exploratory analyses show that patients with unspecified depressive features experience greater rTMS-related symptom improvement compared to those presenting melancholic features. These observations underscore the potential relevance of depressive subtypes in treatment response and warrant confirmation in larger, controlled studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.